Recruiting

Observational Study

Sponsor:

University of Alabama at Birmingham

Code:

NCT05898477

Conditions

Lymphoma

Hemophagocytic Lymphohistiocytoses

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.

Conditions

Lymphoma

Hemophagocytic Lymphohistiocytoses

Study ID

NCT05898477

Start date

May 1, 2023

Status verified date

Jan, 2026

Completion date

Jul, 2028

Anticipated

Primary completion date

Jan, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients with lymphoma that are fulfilling at least one of the following:

A. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25>3,900 U/mL and ferritin>1,000 ng/mL)

Exclusion Criteria:

  • Patients developing HLH> 1 month after lymphoma diagnosis (for aggressive lymphomas)
  • Patients with incomplete treatment and response documentation

Study Design

Enrollment

2000 participants

Anticipated

Interventions and Outcome Measures

Arms

Hemophagocytic lymphohistiocytosis (HLH) Patients

Primary outcome measure

  • To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+ [ Time Frame: The participant's survival would be assessed at 180 days from the malignancy diagnosis ]

Central Contacts and Locations

Central contacts

Gaurav Goyal, MD

205-934-1816ggoyal@uabmc.edu

Locations

University of Alabama at Birmingham

Recruiting

Birmingham, Alabama, United States, 35294

Contacts

Gaurav Goyal, MD

2059346770ggoyal@uabmc.edu

More Information

Sponsor

University of Alabama at Birmingham

Last update posted

Jan 22, 2026

Last verified

Jan, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by University of Alabama at Birmingham on 2026-01-22.